Get the Daily Brief
Latest Biotech News
Systimmune’s iza‑bren clears phase III goals in China — survival endpoints met
Systimmune reported that izalontamab brengitecan (iza‑bren), its next‑generation antibody‑drug conjugate, met both progression‑free survival and overall survival endpoints in a phase III trial of...
Mutant p53 reactivation: rezatapopt shows clinical activity in NEJM report
PMV Pharmaceuticals published Phase I results for rezatapopt, a small molecule p53 reactivator selective for the TP53 Y220C mutation, reporting objective responses across multiple tumor types in...
Next‑gen CAR‑T: ultra‑sensitive HIT receptors and receptor knockouts advance solid‑tumor work
Two preclinical advances aim to extend CAR‑T efficacy to solid tumors. Columbia University researchers engineered HLA‑independent T (HIT) receptors that detect vanishingly low CD70 expression and...
ctDNA steers care: blood tests predict bladder outcomes and guide FGFR therapy
Two multicenter studies reinforced circulating tumor DNA’s clinical utility. Fox Chase Cancer Center’s phase 2 RETAIN‑2 trial showed that a ctDNA blood test identified muscle‑invasive bladder...
FDA trial rules shift: one‑trial default and rare‑disease framework spark debate
Regulatory changes at the U.S. Food and Drug Administration are drawing industry scrutiny. The agency’s move toward a one‑adequate‑trial default for marketing authorization has raised questions...
U.S. probe targets Chinese state support and pricing in biotech
The U.S. International Trade Commission opened investigations into Chinese government support and pricing practices in the biotech sector to assess whether state aid and pricing distortions...
Generate Biomedicines prices $400M IPO — AI drug design bet
Generate Biomedicines completed a $400 million initial public offering to fund pivotal trials and platform work. The Flagship Pioneering‑backed company will direct roughly $300 million toward two...
EMA endorses Moderna’s flu–COVID combo — EU clearance likely
European regulators’ human medicines committee recommended approval of Moderna’s mCombriax (mRNA‑1083), a combined influenza and COVID‑19 vaccine for people 50 and older. The CHMP concluded the...
Atrium launches with Avidity’s cardiac RNA assets — $270M war chest
Atrium Therapeutics launched as a San Diego‑based spinout taking on preclinical cardiac RNA programs that were not included in Novartis’s acquisition of Avidity Biosciences. The new company...
EMA’s CHMP backs three orphan drugs — rejects two FDA‑cleared programs
The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approval of three new orphan medicines and declined support for two programs previously cleared by the...
US opens probe into China’s biotech support and pricing — ITC inquiry
U.S. authorities launched a fact‑finding probe into Chinese state support and pricing practices in the biotech sector, initiating investigations by the International Trade Commission. The...
CAR‑T advances for solid tumors: receptor edits and ultra‑sensitive HIT cells
Two independent preclinical advances aim to expand CAR‑T impact in solid tumors. One study reported that knocking out dual prostaglandin E2 (PGE2) receptors in engineered T cells neutralizes an...
Rezatapopt shows proof‑of‑concept in TP53 Y220C tumors — NEJM report
PMV Pharmaceuticals reported Phase I data for rezatapopt, a small molecule designed to reactivate mutant p53 in tumors carrying the TP53 Y220C mutation. Published in the New England Journal of...
ctDNA steers bladder preservation and FGFR therapy decisions
Two studies reinforced circulating tumor DNA’s clinical utility in urothelial cancers. Fox Chase’s RETAIN‑2 phase 2 trial reported that ctDNA can stratify muscle‑invasive bladder cancer patients...
FDA floats 'plausible mechanism' pathway; senators press agency on rare approvals
The FDA proposed a faster 'plausible mechanism' framework aimed at accelerating personalized genomic and ultrarare disease drug development by accepting mechanistic evidence in lieu of large...
Earendil inks up to $885M ADC pact with WuXi XDC — linker license
AI‑driven biologics developer Earendil signed an exclusive deal with WuXi XDC for the WuXiTecan‑2 linker‑payload platform to advance next‑generation antibody‑drug conjugates. Financial terms total...
Moderna’s combo shot clears EU — EMA backs mCombriax
European regulators recommended approval of Moderna’s mCombriax, a combined seasonal influenza and COVID‑19 mRNA vaccine for people aged 50 and older. The European Medicines Agency’s CHMP...
Generate prices $400M IPO — Funds go to phase‑3 asthma push
Generate Biomedicines priced a $400 million IPO, selling 25 million shares at $16 each, to bankroll pivotal phase‑3 trials of its TSLP‑targeting antibody GB‑0895 and additional platform programs....
Avidity spinout Atrium launches — $270M to pursue RNA heart drugs
Atrium Therapeutics formally launched as a spinout from Avidity Biosciences after Novartis completed its $12 billion acquisition of Avidity. The new company, led by former Avidity executives...
FDA’s one‑trial default raises global questions — reviewers, industry push back
The U.S. FDA’s shift toward accepting one adequate, well‑controlled pivotal trial as a default for marketing authorization sparked debate over global consequences. FDA Commissioner Marty Makary...